CNS Pharmaceuticals Inc. is a preclinical stage biotechnology company dedicated to developing innovative anticancer drug candidates for treating primary and metastatic brain and central nervous system tumors. The company's primary focus is on glioblastoma multiforme, an aggressive and currently incurable form of brain cancer, along with other gliomas. CNS Pharmaceuticals maintains a specialized product pipeline including berubicin and CNS-12, targeting serious diseases in neurology and oncology. Founded in 2017 and headquartered in Houston, Texas, the company engages in pioneering research aimed at delivering transformative therapies to improve patient outcomes for individuals suffering from rare but severe neurological cancers. As a preclinical stage pharmaceutical company, CNS Pharmaceuticals represents a research-focused biotech enterprise working to advance treatment options in an area of significant unmet medical need.